Kubilhan Elmas, Özgür Bilen Basaran, Ali Altýnsoy (Ankara, Turkey)

The purpose of this study was to evaluate the effectiveness of intravitreal injection of bevacizumab for treatment of central serous chorioretinopathy. Seven eyes of 7 patients with chronic central serous chorioretinopathy received an intravitreal bevacizumab (1.25 mg/0.05 ml) injection. At baseline and follow-up visits patients had best corrected visual acuity (BCVA), IOP assessment, dilated fundus examination and OCT imaging. Main outcome measures were the resolution of neurosensory detachment, improvement in visual symptoms and visual acuity. Patients received 2-/+1 intravitreal injections of bevacizumab on average during a follow-up of 30-/+7 weeks. Mean BCVA increased by 2-/+2 lines.